Home > Boards > US OTC > Medical - Drugs > BioXcel Therapeutics Inc (BTAI)

BTAI Analyst Actions: BofA Securities Lifts BioXcel Therapeutics'

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
MiamiGent Member Profile
Member Level 
Followed By 236
Posts 35,959
Boards Moderated 5
Alias Born 08/16/08
160x600 placeholder
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 4/14/2021 5:17:16 PM
Universe Pharmaceuticals, Applied Molecular Transport leads healthcare gainers; AzurRx BioPharma, BioXcel Therapeutics among ... Seeking Alpha - 4/1/2021 11:04:34 AM
BioXcel Therapeutics shares fall after early-stage opioid withdrawal study results Seeking Alpha - 3/31/2021 4:40:00 PM
BioXcel Therapeutics Announces Results of Phase 1b/2 Study of BXCL501 for the Treatment of Opioid Withdrawal Symptoms GlobeNewswire Inc. - 3/31/2021 4:01:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/17/2021 5:01:23 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/15/2021 4:13:39 PM
BioXcel Therapeutics BXCL501 nabs accelerated review in U.S. for agitation in dementia Seeking Alpha - 3/15/2021 7:14:44 AM
BioXcel Therapeutics Receives FDA Breakthrough Therapy Designation for BXCL501 for the Acute Treatment of Agitation Associate... GlobeNewswire Inc. - 3/15/2021 7:00:00 AM
BioXcel Therapeutics seeks marketing approval for BXCL501 Seeking Alpha - 3/11/2021 10:26:13 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/11/2021 7:34:46 AM
BioXcel Therapeutics EPS beats by $0.07 Seeking Alpha - 3/11/2021 7:18:42 AM
BioXcel Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update GlobeNewswire Inc. - 3/11/2021 7:15:00 AM
BioXcel Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for BXCL501 for the Acute Treatment of... GlobeNewswire Inc. - 3/11/2021 7:00:00 AM
BioXcel Therapeutics to Host Fourth Quarter and Full Year 2020 Operating and Financial Results Conference Call and Webcast GlobeNewswire Inc. - 3/4/2021 7:00:00 AM
BioXcel's BXCL501 shows promising results in dementia related agitation Seeking Alpha - 3/3/2021 7:57:56 AM
BioXcel Therapeutics Provides Update on its BXCL501 Program for the Acute Treatment of Dementia Related Agitation GlobeNewswire Inc. - 3/3/2021 7:00:00 AM
BioXcel Therapeutics Appoints June Bray to Board of Directors GlobeNewswire Inc. - 3/1/2021 7:00:00 AM
BioXcel starts mid-stage BXCL501 trial for treatment of delirium related agitation Seeking Alpha - 2/25/2021 7:16:56 AM
BioXcel Therapeutics Announces Initiation of Phase 2 PLACIDITY Trial of BXCL501 for the Treatment of Delirium Related Agitati... GlobeNewswire Inc. - 2/25/2021 7:00:00 AM
BioXcel Therapeutics Appoints Javier Rodriguez as Chief Legal Officer and Corporate Secretary GlobeNewswire Inc. - 2/23/2021 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/18/2021 4:57:06 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/16/2021 5:40:15 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/16/2021 5:39:16 PM
Annual Statement of Changes in Beneficial Ownership (5) Edgar (US Regulatory) - 2/16/2021 5:35:27 PM
Annual Statement of Changes in Beneficial Ownership (5) Edgar (US Regulatory) - 2/16/2021 5:35:05 PM
MiamiGent Member Level  Monday, 07/20/20 10:27:15 AM
Re: None
Post # of 28 
BTAI Analyst Actions: BofA Securities Lifts BioXcel Therapeutics' Price Target to $63 From $53, Keeps at Buy

BY MT Newswires — 9:25 AM ET 07/13/2020

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
© 2021 InvestorsHub.com, Inc.
Consent Preferences